{"entity":{"id":"nct05825443","kind":"trial","name":"Adjuvant Chemotherapy Combined With Camrelizumab for IIA -IIIA NSCLC Patients","aka":["PANORAMA"],"tldr":"A phase 2 trial of camrelizumab in lung cancer, run by Nanfang Hospital, Southern Medical University, now recruiting.","summary":"Adjuvant Chemotherapy Combined With Camrelizumab for IIA -IIIA NSCLC Patients is a phase 2, interventional study registered as NCT05825443 by Nanfang Hospital, Southern Medical University, with a registry enrolment figure of 57 participants, started 2023-04-10 and due to reach its primary completion in 2026-04-01. Interventions recorded: Camrelizumab. Conditions listed: Immunotherapy; Chemotherapy. Primary outcome: Two-years disease free survival (2y-DFS). Lung eligibility wording from the registry: \"For patients with non-small cell lung cancer who have undergone surgical resection, the TNM stage after surgery is IIA-IIIA;\". Sites: China. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-25","links":[{"label":"ClinicalTrials.gov NCT05825443","url":"https://clinicaltrials.gov/study/NCT05825443"}],"tags":["ctgov-ingest","lung-deep-dive"],"related":[],"cancers":["resectable-nsclc"],"sections":[],"technologies":["checkpoint-inhibitor"],"targets":[],"drugs":["camrelizumab"],"companies":["hengrui"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT05825443","phase":"2","setting":"Efficacy and Safety of Postoperative Adjuvant Chemotherapy Combined With Camrelizumab for Patients With IIA -IIIA Non-small Cell Lung Cancer：a Phase II , Single-arm Clinical Study","sponsor":"Nanfang Hospital, Southern Medical University","enrolled":57,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct05825443/","neighbours":{"cancer":[{"id":"resectable-nsclc","kind":"cancer","name":"Resectable stage I to III non-small-cell lung cancer","route":"/cancers/resectable-nsclc/"}],"technology":[{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"}],"drug":[{"id":"camrelizumab","kind":"drug","name":"Camrelizumab","route":"/drugs/camrelizumab/"}],"company":[{"id":"hengrui","kind":"company","name":"Jiangsu Hengrui Pharmaceuticals","route":"/companies/hengrui/"}],"term":[{"id":"lung-trials-open-today","kind":"term","name":"Lung cancer trials open today (registry snapshot)","route":"/terms/lung-trials-open-today/"}]}}